Bicycle Therapeutics PLC
BCYC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761612
In the last 90 days, Bicycle Therapeutics PLC insiders filed 0 open-market purchases and 5 sales; 103 institutions reported holding it in 13F filings for Q2 2026, worth $157.9M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Bicycle Therapeutics PLC insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 5 filings
- 5 insiders, $60.5K in total
- Insiders trading
- 5
- Net value
- −$60.5K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Bicycle Therapeutics PLC, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Thompson Travis Alvin | Chief Financial Officer | 64,441 | Jul 17, 2026 | 6 |
| Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 94,375 | Jul 17, 2026 | 5 |
| Skynner Michael | CHIEF SCIENTIFIC OFFICER | 157,171 | Jul 17, 2026 | 5 |
| Perry Jennifer Scott | Chief Operating Officer | 91,052 | Jul 17, 2026 | 3 |
| Lee Kevin | CHIEF EXECUTIVE OFFICER | 603,671 | Jul 7, 2026 | 4 |
| Baker Julian | Director, 10% Owner | 10,018,674Indirect | Jan 6, 2026 | 1 |
| Baker Felix | Director, 10% Owner | 10,018,674Indirect | Jan 6, 2026 | 1 |
| Baker Bros. Advisors LP | Director, 10% Owner | 10,018,674Indirect | Jan 6, 2026 | 1 |
| Baker Brothers Life Sciences LP | Director, 10% Owner | 10,018,674Indirect | Jan 6, 2026 | 1 |
| 667, L.P. | Director, 10% Owner | 10,018,674Indirect | Jan 6, 2026 | 1 |
| Baker Bros. Advisors (GP) LLC | Director, 10% Owner | 10,018,674Indirect | Jan 6, 2026 | 1 |
| Hoppenot Herve | Director | 15,532 | Jan 6, 2026 | 1 |
| Gutierrez-Ramos Jose-Carlos | Director | 32,500 | Jan 6, 2026 | 1 |
| Dansey Roger D | Director | 15,532 | Jan 6, 2026 | 1 |
| Winter Gregory Paul | Director | 196,427 | Jan 6, 2026 | 1 |
| Bourque Janice | Director | 32,500 | Jan 6, 2026 | 1 |
| Riva Alessandro | Director | 19,880 | Jan 6, 2026 | 1 |
| Milnes Alistair | CHIEF OPERATING OFFICER | 136,717 | Jan 6, 2026 | 2 |
| Sands Stephen H. | Director | 26,893 | Jan 6, 2026 | 1 |
| Young Alethia | Chief Financial Officer | 87,081 | Jan 6, 2026 | 2 |
| Swanton Robert Charles | Director | 19,213 | Jan 6, 2026 | 2 |
| Westin Eric | Chief Medical Officer | – | Mar 27, 2025 | 0 |
| Kender Richard N | Director | 23,000 | Jan 6, 2025 | 0 |
| Legault Pierre | Director | 46,000 | Jan 6, 2025 | 0 |
| Arroyo Santiago | CHIEF DEVELOPMENT OFFICER | 69,057 | Jan 6, 2025 | 0 |
| Crockett Nigel | CHIEF BUSINESS OFFICER | 51,053 | Jan 6, 2025 | 0 |
| Keen Nicholas | CHIEF SCIENTIFIC OFFICER | 62,024 | Jul 8, 2024 | 0 |
| Jordan Veronica GH | Director | 16,750 | Jan 4, 2024 | 0 |
| Kalowski Lee | President and CFO | 30,309 | Apr 5, 2023 | 0 |
| Smethurst Dominic | Chief Medical Officer | 36,699 | Jan 5, 2023 | 0 |
| Bingham Kate | Director | 38,708Indirect | Jul 20, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2021 (view filing) | Sep 15-16 | 2 days | Keen NicholasChief Scientific Officer | SSale | −4.96K | $45.00 | −$223.0K | −59.5%3.37K after | 2 lots |
| Sep 3, 2021 (view filing) | Sep 2 | 1 day | Kalowski LeePresident and CFO | SSale | −10.0K | $40.00 | −$400.0K | −100.0%0 after | |
| Sep 3, 2021 (view filing) | Sep 2 | 1 day | Keen NicholasChief Scientific Officer | SSale | −10.0K | $40.00 | −$400.0K | −54.6%8.32K after | |
| Sep 3, 2021 (view filing) | Sep 1-2 | 2 days | Lee KevinChief Executive Officer | SSale | −32.1K | $37.65 | −$1.21M | −12.0%235.1K after | 4 lots |
| Aug 31, 2021 (view filing) | Aug 27-31 | 4 days | Lee KevinChief Executive Officer | SSale | −13.0K | $36.28 | −$472.9K | −5.1%244.3K after | 3 lots |
| Aug 27, 2021 (view filing) | Aug 26-27 | 1 day | Kalowski LeePresident and CFO | SSale | −8.50K | $35.14 | −$298.7K | −100.0%0 after | 2 lots |
| Aug 25, 2021 (view filing) | Aug 23 | 2 days | Kalowski LeePresident and CFO | SSale | −7.50K | $33.02 | −$247.7K | −100.0%0 after | |
| Jul 30, 2021 (view filing) | Jul 29 | 1 day | Kalowski LeePresident and CFO | SSale | −12.5K | $31.51 | −$393.8K | −100.0%0 after | 3 lots |
| Jul 27, 2021 (view filing) | Jul 23-26 | 4 days | Lee KevinChief Executive Officer | SSale | −4.88K | $36.02 | −$175.8K | −2.0%245.1K after | 2 lots |
| Jul 20, 2021 (view filing) | Jul 13-14 | 7 days | Bingham KateDirector | SSale | −44.9K | $34.00 | −$1.53M | −53.7%38.7K after | Amended4 lots |
| Jul 16, 2021 (view filing) | Jul 14 | 2 days | Keen NicholasChief Scientific Officer | SSale | −10.0K | $35.00 | −$350.0K | −35.3%18.3K after | |
| Jul 16, 2021 (view filing) | Jul 15-16 | 1 day | Lee KevinChief Executive Officer | SSale | −22.6K | $34.27 | −$773.8K | −8.4%245.1K after | 2 lots |
| Jul 14, 2021 (view filing) | Jul 12-13 | 2 days | Crockett NigelChief Business Officer | SSale | −79.7K | $32.40 | −$2.58M | −100.0%0 after | 3 lots |
| Jul 14, 2021 (view filing) | Jul 12-14 | 2 days | Lee KevinChief Executive Officer | SSale | −55.4K | $33.30 | −$1.84M | −18.4%245.1K after | 8 lots |
| Jul 8, 2021 (view filing) | Jul 6 | 2 days | Crockett NigelChief Business Officer | SSale | −271 | $32.00 | −$8.67K | −100.0%0 after |